natgillin/translations-raw huggingface dataset:
Caution should be exercised when therapy is administered to patients with pretreatment elevated transaminases ( &gt; the upper limit of the normal ranges and &lt; 3 times the upper limit of the normal range);
O oprezu pri davanju lijeka bolesnicima s povišenim transaminazama prije početka terapije ( &gt; od gornje granice referentnih raspona i  3 puta gornja granica referentnog raspona);
Caution should be exercised when Thymanax is administered to patients with pretreatment elevated transaminases ( &gt; the upper limit of the normal ranges and 3 times the upper limit of the normal range).
Potreban je oprez kada se Thymanax primijenjuje kod bolesnika kod kojih su transaminaze povišene bile prije liječenja ( &gt; gornje granice od normalnog raspona i ≤3 puta gornja granica od normalnog raspona).
Caution should be exercised when using ONIVYDE in patients with body mass index &lt; 18.5 kg/m2.
Potreban je oprez pri primjeni lijeka ONIVYDE u bolesnika s indeksom tjelesne mase &lt; 18,5 kg/m2.
Caution should be exercised when Valdoxan is administered to patients with pretreatment elevated transaminases ( &gt; the upper limit of the normal ranges and 3 times the upper limit of the normal range).
Potreban je oprez kada se Valdoxan primijenjuje kod bolesnika kod kojih su transaminaze povišene bile prije liječenja ( &gt; gornje granice od normalnog raspona i ≤3 puta gornja granica od normalnog raspona).
CD20+ grade 1 or 2 follicular lymphoma; stage III or IV at diagnosis; normal peripheral blood cell counts; &lt; 25% bone marrow involvement; age ≥ 18 yrs; and complete response (CR/Cru) or partial response (PR) after first-line chemotherapy determined by physical examination, CT scans and bone marrow biopsy.
CD20+ folikularni limfom 1. ili 2. stupnja, stadij III ili IV u trenutku dijagnoze, uredna krvna slika, zahvaćeno &lt; 25 % koštane srži, dob ≥ 18 godina te potpuni odgovor (CR/CRu) ili djelomični odgovor (PR) nakon prve linije kemoterapije utvrđen fizikalnim pregledom, CT-om i biopsijom koštane srži.
CD4 count &lt; 350 cells/μl, n (%)
broj CD4 stanica &lt; 350 stanica/μl, n (%)
CD4-count &lt; 50
Broj CD4 &lt; 50
CDAI &lt; 150 at both week 30 and 54 and not receiving corticosteroids in the 3 months prior to week 54 among patients who were receiving corticosteroids at baseline.
CDAI &lt; 150 i u 30. i u 54. tjednu, bez uzimanja kortikosteroida tijekom 3 mjeseca prije 54. tjedna u bolesnika koji su primali kortikosteroide na početku ispitivanja.
CDAI &lt; 150 at both Week 30 and 54 and not receiving corticosteroids in the 3 months prior to Week 54 among patients who were receiving corticosteroids at baseline.
CDAI &lt; 150 i u 30. i u 54. tjednu, bez uzimanja kortikosteroida tijekom 3 mjeseca prije 54. tjedna u bolesnika koji su primali kortikosteroide na početku ispitivanja.
CE/bazedoxifene has not been studied in women with baseline triglyceride levels &gt; 300 mg/dL ( &gt; 3.4 mmol/L).
Konjugirani estrogeni/bazedoksifen nisu ispitivani u žena u kojih je početna razina triglicerida &gt; 300 mg/dL ( &gt; 3,4 mmol/L).
CELSENTRI should be used with caution in patients with severe renal impairment (CLcr &lt; 30 mL/min) who are receiving potent CYP3A4 inhibitors (see sections 4.4 and 5.2).
CELSENTRI treba primjenjivati s oprezom u bolesnika s teškim oštećenjem bubrega (klirens kreatinina &lt; 30 ml/min) koji uzimaju snažne inhibitore CYP3A4 (vidjeti dijelove 4.4 i 5.2).
CEPROTIN should be administered at a maximum injection rate of 2 ml per minute except for children with a body weight of &lt; 10 kg, where the injection rate should not exceed a rate of 0.2 ml/kg/min.
CEPROTIN je potrebno primjenjivati maksimalnom brzinom injiciranja od 2 ml u minuti, osim kod djece s tjelesnom težinom &lt; 10 kg pri čemu brzina injiciranja ne smije prijeći 0,2 ml/kg/min.
Cessation of therapy is recommended when platelet count decreases to levels &lt; 25,000/mm3.
Kada razina trombocita padne na &lt; 25 000/mm3, preporučuje se prekid liječenja.
CGI-I responder rates (improved, very much improved) were 51.2% and 72.0% for placebo and pramipexole, respectively (difference 20% CI 95%: 8.1%; 31.8%, p &lt; 0.0005).
Stope bolesnika s odgovorom prema CGI-I (poboljšanje, poboljšanje u velikoj mjeri) bile su 51,2% za placebo i 72,0% za pramipeksol (razlika 20% CI 95%: 8,1%; 31,8%, p &lt; 0,0005).
CGI-I responder rates (much improved, very much improved) were 43.0% and 67.5% for placebo and rotigotine respectively (difference 24.5% CI 95%: 14.2%; 34.8%, p &lt; 0.0001).
Stope bolesnika s odgovorom prema CGI-1 (dosta poboljšan, jako poboljšan) bile su 43,0% za placebo i 67,5% za rotigotin (razlika 24,5% CI95%: 14,2%; 34,8%, p &lt; 0,0001).
Change in Hgb &gt; 20g/L, n (%) (95% CI)
Promjena Hgb &gt; 20 g/l, n (%) (95% CI)
Changes in fasting glucose from borderline at baseline (≥ 5.56 - &lt; 7 mmol/l) to high (≥ 7 mmol/l) were very common.
Promjene GUK-a natašte od graničnih vrijednosti na početku (≥ 5,56 - &lt; 7 mmol/l) do visokih (≥ 7 mmol/l) bile su vrlo česte.
Changes in fasting glucose from borderline at baseline (≥ 5.56 - &lt; 7 mmol/l) to high (≥ 7 mmol/l) were very common.
Promjene u vrijednosti glukoze natašte od početnih graničnih vrijednosti (≥ 5,56- &lt; 7 mmol/l) do visokih vrijednosti (≥ 7 mmol/l) bile su vrlo česte.
Changes in fasting glucose from borderline at baseline (≥ 5.56 - &lt; 7 mmol/l) to high (≥ 7 mmol/l) were very common.
Promjene vrijednosti glukoze natašte od početnih graničnih vrijednosti (≥ 5,56- &lt; 7 mmol/l) do visokih vrijednosti (≥ 7 mmol/l) bile su vrlo česte.
Changes in fasting glucose from borderline at baseline (≥ 5.56- &lt; 7 mmol/l) to high (≥ 7 mmol/l) were very common.
Promjene vrijednosti glukoze natašte od početnih graničnih vrijednosti (≥ 5,56- &lt; 7 mmol/l) do visokih vrijednosti (≥ 7 mmol/l) bile su vrlo česte.
Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l - &lt; 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common.
Promjene u vrijednosti triglicerida natašte od početnih graničnih vrijednosti (≥ 1,69 - &lt; 2,26 mmol/l) do visokih vrijednosti (≥ 2,26 mmol/l) bile su vrlo česte.
Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l - &lt; 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common.
Promjene vrijednosti triglicerida natašte od početnih graničnih vrijednosti (≥ 1,69 - &lt; 2,26 mmol/l) do visokih vrijednosti (≥ 2,26 mmol/l) bile su vrlo česte.
Changes in fasting triglycerides from borderline at baseline (≥ 1.69 mmol/l- &lt; 2.26 mmol/l) to high (≥ 2.26 mmol/l) were very common.
Promjene vrijednosti triglicerida natašte od početnih graničnih vrijednosti (≥ 1,69 - &lt; 2,26 mmol/l) do visokih vrijednosti (≥ 2,26 mmol/l) bile su vrlo česte.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - &lt; 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common.
Promjene ukupnog kolesterola natašte od graničnih vrijednosti na početku (≥ 4,39 - &lt; 5,17 mmol/l) do visokih (≥ 5,17 mmol/l) bile su vrlo česte.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - &lt; 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common.
Vrlo česte su bile promjene ukupnih razina kolesterola natašte od graničnih početnih vrijednosti (≥ 4,39- &lt; 5,17 mmol/l) do visokih (≥ 5,17 mmol/l).
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - &lt; 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common.
Vrlo česte su bile promjene ukupnih razina kolesterola natašte od graničnih početnih vrijednosti (≥ 4,39- &lt; 5,17 mmol/l) do visokih vrijednosti (≥ 5,17 mmol/l).
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39 - &lt; 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common.
Vrlo česte su bile promjene ukupnih razina kolesterola natašte od graničnih početnih vrijednosti (≥ 4,39- &lt; 5,17 mmol/l) do visokih vrijednosti(≥ 5,17 mmol/l).
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39- &lt; 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common.
Vrlo česte su bile promjene ukupnih razina kolesterola natašte od graničnih početnih vrijednosti (≥ 4,39- &lt; 5,17 mmol/l) do visokih (≥ 5,17 mmol/l).
Changes in total fasting cholesterol levels from borderline at baseline (≥ 4.39- &lt; 5.17 mmol/l) to high (≥ 5.17 mmol/l) were very common.
Vrlo česte su bile promjene ukupnih razina kolesterola natašte od graničnih početnih vrijednosti (≥ 4,39– &lt; 5,17 mmol/l) do visokih (≥ 5,17 mmol/l).
Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17 - &lt; 6.2 mmol/l) to high (≥ 6.2 mmol/l) were very common.
Promjene ukupnog kolesterola natašte od graničnih vrijednosti na početku (≥ 5,17 - &lt; 6,2 mmol/l) do visokih (≥ 6,2 mmol/l) bile su vrlo česte.
Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17- &lt; 6.2 mmol/l) to high (≥ 6.2 mmol/l) were very common.
Promjene ukupnog kolesterola natašte od početnih graničnih vrijednosti (≥ 5,17- &lt; 6,2 mmol/l) do visokih vrijednosti (≥ 6,2 mmol/l) bile su vrlo česte.
Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently &gt; 800 µg/l).
Kelacijska se terapija započinje kad postoji dokaz preopterećenja željezom (koncentracija željeza u jetri [LIC, engl. liver iron concentration] ≥5 mg Fe/g težine suhog tkiva jetre ili serumskog feritina dosljedno &gt; 800 µg/l).
chewable tablets for dogs &gt; 10–25 kg
tablete za žvakanje za pse 10 – 25 kg
chewable tablets for dogs &gt; 15–30 kg
Tablete za žvakanje za pse &gt; 15-30 kg
chewable tablets for dogs &gt; 15–30 kg
Tablete za žvakanje za pse &gt; 15–30 kg
chewable tablets for dogs &gt; 25–50 kg
tablete za žvakanje za pse 25 – 50 kg
chewable tablets for dogs &gt; 3.5–7.5 kg
Tablete za žvakanje za pse &gt; 3,5–7,5 kg
chewable tablets for dogs &gt; 30–60 kg
Tablete za žvakanje za pse &gt; 30-60 kg
chewable tablets for dogs &gt; 30–60 kg
Tablete za žvakanje za pse &gt; 30–60 kg
chewable tablets for dogs &gt; 4–10 kg
tablete za žvakanje za pse 4 – 10 kg
chewable tablets for dogs &gt; 7.5–15 kg
Tablete za žvakanje za pse &gt; 7,5-15 kg
chewable tablets for dogs &gt; 7.5–15 kg
Tablete za žvakanje za pse &gt; 7,5–15 kg
Childhood-onset: In patients with childhood-onset isolated GHD (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be performed after completion of growth, except for those having low insulin-like growth factor-I (IGF-I) concentrations ( &lt; -2 standard deviation score (SDS)), who may be considered for one test.
Nastanak u djetinjstvu: U bolesnika u kojih je izolirani NHR nastao u djetinjstvu (nema dokaza hipotalamičko-pituitarne bolesti niti zračenja glave) moraju se napraviti dva dinamička testa nakon završetka rasta, osim kod onih s niskim koncentracijama inzulinu sličnog čimbenika rasta-1 (IGF-I) (skor &lt; -2 standardne devijacije (SDS)), kod kojih se može razmotriti jedan test.
Children (2 to &lt; 12 years) and young adolescents with low body weight (12 to 14 years and &lt; 50 kg) Voriconazole should be dosed as children as these young adolescents may metabolize voriconazole more similarly to children than to adults.
Djeca (2 do &lt; 12 godina) i mlađi adolescenti male tjelesne težine (12 do 14 godina i &lt; 50 kg) Vorikonazol se treba dozirati kao kod djece jer mlađi adolescenti mogu metabolizirati vorikonazol sličnije djeci nego odraslima.
Children (3- &lt; 9 years)
Djeca (3- &lt; 9 godina)
Children (6 to &lt; 12 years of age)
Djeca (6 do &lt; 12 godina starosti)
Children ( &lt; 18 years)
Djeca ( &lt; 18 godina)
Children (including neonates) and adolescents &lt; 16 years of age:
Djeca (uključujući novorođenčad) i adolescenti u dobi &lt; 16 godina:
Children (including neonates) and adolescents &lt; 16 years of age:
Djeca (uključujući novorođenčad) i adolescenti u dobi ˂ 16 godina:
Children 2 to &lt; 4 years of age:
Djeca u dobi od 2 do &lt; 4 godine:
Children 2 to &lt; 6
Djeca 2 do &lt; 6
Children 2- &lt; 4 years of age or children  4 years of age  7.5 kg and &lt; 15 kg
Djeca u dobi od 2 do &lt; 4 godine ili djeca u dobi od 4 godine i 7,5 kg i &lt; 15 kg
Children 3 - &lt; 5 years
Djeca 3 - &lt; 5 godina
Children 6 to &lt; 12
Djeca 6 do &lt; 12
Children 6 to &lt; 12 years of age
Djeca od 6 do &lt; 12 godina starosti
Children &lt; 1 year old
Djeca u dobi &lt; 1 godine
Children &lt; 52
Djeca &lt; 5 godina2
Children &lt; 7 years (sildenafil combined dose = 47; placebo = 16) were evaluable only for the secondary endpoints.
U djece mlađe od 7 godina (kombinirane doze sildenafila = 47; placebo = 16) mogli su se procijeniti samo sekundarni ishodi.
Children &gt; 1 month post-natal, predominantly post-operative, have been evaluated for treatment up to 24 hours in the ICU and demonstrated a similar safety profile as in adults.
Kod djece &gt; 1 mjececa postnatalno, pretežno nakon kirurškog zahvata, procijenjivane za liječenje do 24 sata u jedinici intenzivnog liječenja pokazao se sličan sigurnosni profil kao kod odraslih.
Children aged 8 to &lt; 12 years: 1.2 mg/kg of tigecycline every 12 hours intravenously to a maximum dose of 50 mg every 12 hours for 5 to 14 days.
Djeca u dobi od 8 do &lt; 12 godina: 1,2 mg/kg tigeciklina svakih 12 sati u venu do maksimalne doze od 50 mg svakih 12 sati tijekom 5 do 14 dana.
Children aged from 2 months to &lt; 12 years and adolescents aged from 12 to &lt; 18 years with bodyweight &lt; 33 kg: see Table 2.
Djeca u dobi od navršena 2 mjeseca do &lt; 12 godina i adolescenti u dobi od navršenih 12 do &lt; 18 godina čija je tjelesna težina &lt; 33 kg: vidjeti Tablicu 2.
Children and adolescents ( &lt; 18 years of age)
Djeca i adolescenti ( &lt; 18 godina starosti)
Children and adolescents ( &lt; 18 years)
Djeca i adolescenti (u dobi do 18 godina)
Children and adolescents aged ≥ 3 to &lt; 18 years received two vaccine doses of 0.5ml and children aged ≥ 2 months to &lt; 3 years received two vaccine doses of 0.25ml on Day 0 and Day 28 by intramuscular injection.
Djeca i adolescenti u dobi od ≥ 3 do &lt; 18 godina primili su dvije doze cjepiva od 0,5 ml, a djeca u dobi od ≥ 2 mjeseca do &lt; 3 godine primila su dvije doze cjepiva od 0,25 ml na 0. i 28. dan, intramuskularnom injekcijom.
Children and adolescents from 3 years to &lt; 18 years of age
Djeca i adolescenti u dobi od 3 godine do &lt; 18 godina
Children and adolescents from 3 years to &lt; 18 years of age should receive a single 0.5 ml booster dose.
Djeca i adolescenti u dobi od 3 godine do &lt; 18 godina trebaju obaviti docjepljivanje jednom dozom cjepiva od 0,5 ml.
Children from 14 months to &lt; 3 years of age should receive a single 0.25 ml booster dose.
Djeca u dobi od 14 mjeseci do &lt; 3 godine trebaju obaviti docjepljivanje jednom dozom cjepiva od 0,25 ml.
Children from 2 months to &lt; 3 years of age
Djeca u dobi od 2 mjeseca do &lt; 3 godine
Children weighing 14 kg to &lt; 20 kg: The recommended dose is 150 mg daily.
Djeca tjelesne težine od 14 kg do &lt; 20 kg: Preporučena doza je 150 mg na dan.
Children weighing 14 to &lt; 20 kg: The recommended dose is 150 mg daily.
Djeca tjelesne težine od 14 kg do &lt; 20 kg: Preporučena doza je 150 mg na dan.
Children weighing 14 to &lt; 20 kg: The recommended dose is 300 mg daily.
Djeca tjelesne težine od 14 do &lt; 20 kg: Preporučena doza je 300 mg na dan.
Children weighing &lt; 20 kg
Djeca tjelesne težine &lt; 20 kg
Children weighing &gt; 40 kg and who are able to swallow capsules may receive prophylaxis with a 75 mg capsule once daily for 10 days as an alternative to the recommended dose of Tamiflu suspension.
Djeca tjelesne težine &gt; 40 kg koja mogu progutati kapsule, umjesto preporučene doze Tamiflu suspenzije također mogu dobivati profilaktičku dozu u obliku kapsule od 75 mg jednom dnevno tijekom 10 dana.
Children weighing &gt; 40 kg and who are able to swallow capsules may receive prophylaxis with a 75 mg capsule once daily for 10 days as an alternative to the recommended dose of Tamiflu suspension.
Djeca tjelesne težine &gt; 40 kg koja mogu progutati kapsule, umjesto preporučene doze Tamiflu suspenzije, također mogu dobivati profilaktičku dozu u obliku kapsule od 75 mg jednom dnevno tijekom 10 dana.
Children weighing &gt; 40 kg and who are able to swallow capsules may receive treatment with the adult dosage of 75 mg capsules twice daily for 5 days as an alternative to the recommended dose of Tamiflu suspension.
Djeca tjelesne težine &gt; 40 kg koja mogu progutati kapsule, umjesto preporučene doze Tamiflu suspenzije također mogu dobivati terapijsku dozu u obliku kapsule od 75 mg dvaput dnevno tijekom 5 dana.
Children weighing &gt; 50 kg received 2 mg/day Resolor tablets or matching placebo.
Djeca tjelesne težine &gt; 50 kg primala su 2 mg/dan lijeka Resolor u obliku tableta ili odgovarajućeg placeba.
Children weighing ≥ 20 kg to &lt; 25 kg: The recommended dose is 450 mg daily.
Djeca tjelesne težine od ≥ 20 kg do &lt; 25 kg: Preporučena doza je 450 mg na dan.
Children weighing ≥ 20 kg to &lt; 25 kg: The recommended dose is 225 mg daily.
Djeca tjelesne težine od ≥ 20 kg do &lt; 25 kg: Preporučena doza je 225 mg na dan.
Children weighing ≥20 kg to &lt; 25 kg: The recommended dose is 225 mg daily.
Djeca tjelesne težine od ≥ 20 kg do &lt; 25 kg: Preporučena doza je 225 mg na dan.
Children were eligible when they were aged &lt; 18 years, ≥15 kg in weight, receiving cART that included lopinavir/ritonavir, HIV-1 ribonucleic acid (RNA) &lt; 50 copies/ml for at least 24 weeks and able to swallow tablets.
Djeca su morala biti &lt; 18 godina, ≥ 15 kg tjelesne težine, primati cART koje uključuje lopinavir/ritonavir, imati HIV-1 ribonukleinsku kiselinu (RNK) &lt; 50 kopija/ml najmanje 24 tjedna te su morala moći progutati tablete.
Children who received ProQuad at 4 through 6 years of age after primary immunization with Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc.
Djeca koja su primila ProQuad u dobi između 4 i 6 godina nakon primarne imunizacije živim cjepivom protiv varičele (Oka/Merck) i cjepivom protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc.
Children who received ProQuad at 4 through 6 years of age after primary vaccination with Varicella Vaccine live (Oka/Merck) and the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc.
Djeca koja su primila ProQuad u dobi između 4 i 6 godina nakon primarnog cijepljenja živim cjepivom protiv varičele (Oka/Merck) i cjepivom protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc.
Children with a body surface area &lt; 0.6 m² should receive 82.5 U (equivalent to 0.1 ml Oncaspar)/kg body weight every 14 days.
Djeca tjelesne površine &lt; 0,6 m² trebaju primati 82,5 U (što odgovara 0,1 ml Oncaspara)/kg tjelesne težine svakih 14 dana.
Cholib is contraindicated in patients with moderate to severe renal insufficiency whose estimated glomerular filtration rate is &lt; 60 mL/min/1.73 m2 (see section 4.3).
Cholib je kontraindiciran u bolesnika s umjerenom do teškom insuficijencijom bubrega čija je procijenjena brzina glomerularne filtracije &lt; 60 ml/min/1,73 m2 (vidjeti dio 4.3).
CHR: ANC &gt; 1.5 x 109/l, platelets &gt; 100x109/l, no blood blasts, BM blasts &lt; 5% and no extramedullary disease
PHO: ABN &gt; 1.5 x 109/l, trombociti &lt; 100 x 109/l, bez blasta u krvi, blast KS &lt; 5% i bez ekstramedularne bolesti
CHR: In study 0102 [ANC ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, no blood blasts, BM blasts &lt; 5% and no extramedullary disease]
CHR: U studiji 0102 [ABN ≥1,5 x 109/l, trombociti ≥100 x 109/l, nema blasta u krvi, blasti u KS &lt; 5% i bez ekstramedularne bolesti]
CHR: Study 0110 [WBC &lt; 10 x 109/l, platelets &lt; 450 x 109/l, myelocyte+metamyelocyte &lt; 5% in blood, no blasts and promyelocytes in blood, basophils &lt; 20%, no extramedullary involvement] and in studies 0102 and 0109 [ANC ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, no blood blasts, BM blasts &lt; 5% and no extramedullary disease]
CHR: Studija 0110 [L &lt; 10 x 109/l, trombociti &lt; 450 x 109/l, mijelociti+metamijelociti &lt; 5% u krvi, u krvi nema blasta i promijelocita, bazofili &lt; 20%, nema ekstramedularne zahvaćenosti], a u studijama 0102 i 0109 [ABN ≥1,5 x 109/l, trombociti ≥100 x 109/l, nema blasta u krvi, blasti u KS &lt; 5% i nema ekstramedularne bolesti]
CHR: Study 0110 [WBC &lt; 10 x 109/l, platelets &lt; 450 x 109/l, myelocyte+metamyelocyte &lt; 5% in blood, no blasts and promyelocytes in blood, basophils &lt; 20%, no extramedullary involvement] and in studies 0102 and 0109 [ANC  1.5 x 109/l, platelets  100 x 109/l, no blood blasts, BM blasts &lt; 5% and no extramedullary disease]
CHR: Studija 0110 [WBC &lt; 10 x 109/l, trombociti &lt; 450 x 109/l, mijelociti+metamijelociti &lt; 5% u krvi, u krvi nema blasta i promijelocita, bazofili &lt; 20%, nema ekstramedularne zahvaćenosti], a u studijama 0102 i 0109 [ABN ≥1,5 x 109/l, trombociti ≥100 x 109/l, nema blasta u krvi, blasti u KS &lt; 5% i nema ekstramedularne bolesti]
CHR: WBC ≤ institutional ULN, ANC ≥ 1,000/mm3, platelets ≥ 100,000/mm3, no blasts or promyelocytes in peripheral blood, bone marrow blasts ≤ 5%, &lt; 5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood &lt; 20%, and no extramedullary involvement.
CHR: broj leukocita ≤ GGN za laboratorij, ABN ≥ 1000/mm3, trombociti ≥ 100 000/mm3, bez blasta ili promijelocita u perifernoj krvi, blasti u koštanoj srži ≤ 5%, &lt; 5% mijelocita plus metamijelocita u perifernoj krvi, bazofili u perifernoj krvi &lt; 20%, i bez ekstramedularne infiltracije.
Chronic hepatitis B: In adolescents aged 12 to &lt; 18 years and weighing ≥ 35 kg, the recommended dose of Viread is 245 mg (one tablet) once daily, taken orally with food (see sections 4.8 and 5.1).
Kronični hepatitis B: U adolescenata u dobi od 12 do &lt; 18 godina i tjelesne težine ≥ 35 kg, preporučena doza Vireada je 245 mg (jedna tableta) jedanput na dan koja se uzima peroralno s hranom (vidjeti dijelove 4.8 i 5.1).
Chronic hepatitis B: In study GS-US-174-0115, 106 HBeAg negative and HBeAg positive patients aged 12 to &lt; 18 years with chronic HBV infection [HBV DNA ≥ 105 copies/ml, elevated serum ALT (≥ 2 x ULN) or a history of elevated serum ALT levels in the past 24 months] were treated with tenofovir disoproxil 245 mg (as fumarate) (n = 52) or placebo (n = 54) for 72 weeks.
Kronični hepatitis B: U ispitivanju GS-US-174-0115, 106 HBeAg-negativnih i HBeAg-pozitivnih pacijenata u dobi od 12 do &lt; 18 godina s kroničnom HBV-infekcijom [HBV DNK ≥ 105 kopija/ml, povišeni ALT (≥ 2 x ULN) u serumu ili povišene razine ALT-a u serumu u prethodna 24 mjeseca] bilo je liječeno tenofovirdizoproksilom od 245 mg (u obliku tenofovirdizoproksilfumarata) (n = 52) ili je primalo placebo (n = 54) tijekom 72 tjedna.
Chronic hepatitis B: In study GS-US-174-0115, 106 HBeAg negative and HBeAg positive patients aged 12 to &lt; 18 years with chronic HBV infection [HBV DNA ≥ 105 copies/ml, elevated serum ALT (≥ 2 x ULN) or a history of elevated serum ALT levels in the past 24 months] were treated with tenofovir disoproxil 245 mg (as fumarate) (n = 52) or placebo (n = 54) for 72 weeks.
Kronični hepatitis B: U ispitivanju GS-US-174-0115, 106 HBeAg-negativnih i HBeAg-pozitivnih pacijenata u dobi od 12 do &lt; 18 godina s kroničnom HBV-infekcijom [HBV DNK ≥ 105 kopija/ml, povišeni ALT (≥ 2 x ULN) u serumu ili povišene razine ALT-a u serumu u prethodna 24 mjeseca] bilo je liječeno tenofovirdizoproksilom od 245 mg (uu obliku tenofovirdizoproksilfumarata) (n = 52) ili je primalo placebo (n = 54) tijekom 72 tjedna.